(J Am Heart Assoc. 2016;5:e003231 doi: [10.1161/JAHA.116.003231](10.1161/JAHA.116.003231))

Introduction {#jah31718-sec-0004}
============

Hypertension is the most prevalent, modifiable, and costly risk factor for cardiovascular disease (CVD).[1](#jah31718-bib-0001){ref-type="ref"} Nearly ≈33% (80 million) of US adults currently have hypertension,[1](#jah31718-bib-0001){ref-type="ref"} and by 2030, this number is projected to reach 41.1%.[1](#jah31718-bib-0001){ref-type="ref"}, [2](#jah31718-bib-0002){ref-type="ref"} Lifestyle‐related factors have been identified as the only modifiable determinants of hypertension.[2](#jah31718-bib-0002){ref-type="ref"} As a result, numerous randomized controlled trials (RCTs) and over 33 meta‐analyses[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"} have investigated the antihypertensive effects of exercise. Collectively, these meta‐analyses concluded that aerobic exercise (AE) lowers blood pressure (BP) 5 to 7 mm Hg, whereas dynamic resistance training (RT) lowers BP 2 to 3 mm Hg among adults with hypertension.[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} Accordingly, 30 to 60 min/day of moderate‐intensity AE is recommended on most days of the week supplemented by moderate‐intensity dynamic RT on ≥2 days/week to prevent, treat, and control hypertension.[4](#jah31718-bib-0004){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} Yet, a more‐critical review of this literature revealed considerable variability in the magnitude of the BP reductions following both AE (ie, 1--9 mm Hg) and dynamic RT (ie, 0--6 mm Hg), for reasons that are not clear.[4](#jah31718-bib-0004){ref-type="ref"}

In contrast to the strong evidence supporting the BP‐lowering effects of AE, there is much weaker and limited evidence supporting the efficacy of dynamic RT as stand‐alone antihypertensive therapy.[4](#jah31718-bib-0004){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} In addition to several reviews,[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} 6 meta‐analyses to date have exclusively examined the BP‐lowering effects of dynamic RT,[7](#jah31718-bib-0007){ref-type="ref"}, [8](#jah31718-bib-0008){ref-type="ref"}, [9](#jah31718-bib-0009){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"}, [12](#jah31718-bib-0012){ref-type="ref"} which included mostly healthy adults with normal BP and prehypertension. Importantly, none of these meta‐analyses completely satisfied contemporary methodological quality standards[3](#jah31718-bib-0003){ref-type="ref"}, [13](#jah31718-bib-0013){ref-type="ref"}, [14](#jah31718-bib-0014){ref-type="ref"}, [15](#jah31718-bib-0015){ref-type="ref"} nor were they able to identify important sample or dynamic RT characteristics that modulated the BP response to dynamic RT. Meta‐analyses routinely cited poor reporting,[7](#jah31718-bib-0007){ref-type="ref"}, [9](#jah31718-bib-0009){ref-type="ref"} low methodological study quality,[10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"} and the small number of RT studies[7](#jah31718-bib-0007){ref-type="ref"}, [8](#jah31718-bib-0008){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"} as limitations of their meta‐analyses, and hence, lack of significant findings. Yet, meta‐analyses rarely examined how methodological study quality influenced their study results,[8](#jah31718-bib-0008){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"} applied stringent inclusionary criteria,[9](#jah31718-bib-0009){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [12](#jah31718-bib-0012){ref-type="ref"} and used subgroup analysis to investigate potential moderators, an approach that is less precise than other conventional techniques, especially among small samples.[16](#jah31718-bib-0016){ref-type="ref"}, [17](#jah31718-bib-0017){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"}, [19](#jah31718-bib-0019){ref-type="ref"} Because of these notable limitations, previous meta‐analyses likely underestimated the antihypertensive effects of dynamic RT, calling into question the generalizability of their findings to adult populations with high BP.[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}

Several primary level studies have shown that systolic BP (SBP)/diastolic BP (DBP) reductions following dynamic RT are comparable to that of AE among adults with hypertension,[20](#jah31718-bib-0020){ref-type="ref"} reporting SBP/DBP reductions of ≈7 to 16/6 to 12 mm Hg and ≈10 to 14/1 to 4 mm Hg among adults with untreated[21](#jah31718-bib-0021){ref-type="ref"}, [22](#jah31718-bib-0022){ref-type="ref"}, [23](#jah31718-bib-0023){ref-type="ref"} and controlled[24](#jah31718-bib-0024){ref-type="ref"}, [25](#jah31718-bib-0025){ref-type="ref"}, [26](#jah31718-bib-0026){ref-type="ref"} hypertension, respectively. Although limited, controlled studies directly comparing the effectiveness of AE and dynamic RT as antihypertensive therapy found that dynamic RT reduced BP to similar levels as AE[20](#jah31718-bib-0020){ref-type="ref"} among adults with untreated (≈7--14/6--8 mm Hg)[21](#jah31718-bib-0021){ref-type="ref"}, [23](#jah31718-bib-0023){ref-type="ref"} and controlled (≈10/3 mm Hg)[24](#jah31718-bib-0024){ref-type="ref"}, [27](#jah31718-bib-0027){ref-type="ref"} hypertension.

Therefore, the purposes of our meta‐analysis were to provide more precise estimates regarding the efficacy of dynamic RT as stand‐alone antihypertensive therapy, and identify potential moderators of this response to provide insight into the optimal dose of dynamic RT to lower BP among adults with high BP.

Methods {#jah31718-sec-0005}
=======

This study fully satisfies the criteria implied by the PRISMA Statement (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses),[14](#jah31718-bib-0014){ref-type="ref"}, [15](#jah31718-bib-0015){ref-type="ref"} AMSTAR Methodological Quality Scale (Assessment of Multiple SysTemAtic Reviews),[13](#jah31718-bib-0013){ref-type="ref"}, [28](#jah31718-bib-0028){ref-type="ref"} and AMSTAR~ExBP~, an augmented version of the AMSTAR designed specifically to assess meta‐analyses examining the BP response to exercise.[3](#jah31718-bib-0003){ref-type="ref"} Institutional review board approval was not required for the current research because it is a meta‐analysis of controlled dynamic RT interventions, which is not considered as research involving human subjects.

Inclusion Criteria {#jah31718-sec-0006}
------------------

Controlled studies were eligible for inclusion if they satisfied 4 a priori criteria: (1) involved adult participants (≥19 years);[29](#jah31718-bib-0029){ref-type="ref"}, [30](#jah31718-bib-0030){ref-type="ref"} (2) involved a non‐exercise/non‐diet control or comparison group; (3) reported BP pre‐ and post‐intervention for dynamic RT and control groups; and (4) reported the Frequency, Intensity, and Time (or FIT) of the dynamic RT intervention. Studies involving weight loss drugs, diet therapy, or diet modifications in addition to dynamic RT were excluded. Approximately half of US adults (49.8%)[31](#jah31718-bib-0031){ref-type="ref"} have at least 1 lifestyle‐related chronic health condition (eg, diabetes mellitus, CVD risk factors, etc, that require ongoing medical attention and/or limits activities of daily living[32](#jah31718-bib-0032){ref-type="ref"}, [33](#jah31718-bib-0033){ref-type="ref"}), and of these, another half (25.5%) have 2 or more of these conditions.[31](#jah31718-bib-0031){ref-type="ref"} Given that hypertension usually occurs in conjunction with other metabolically linked CVD risk factors (ie, \<20% occurs in isolation),[34](#jah31718-bib-0034){ref-type="ref"} and more than half of adults with hypertension have a cluster of 2 or more CVD risk factors,[34](#jah31718-bib-0034){ref-type="ref"} we only excluded studies that involved populations with disease(s) or health conditions unrelated to CVD (eg, arthritis, cancer, HIV/AIDS).

Search Strategy {#jah31718-sec-0007}
---------------

In consultation with a medical librarian (J.L.), exhaustive Boolean searches were run in 5 electronic databases from inception until January 31, 2014 to identify all relevant studies. Potentially qualifying reports were retrieved from the following electronic databases: Cumulative Index to Nursing and Allied Health Literature, PubMed (including Medline), Scopus (including EMBASE), SportDiscus, and Web of Science (online supplemental material, Data S1, provides the full search strategy for each electronic database). Four investigators (H.V.M., T.U.G., K.C.F., and L.M.L.) screened the sample for inclusion with duplication of effort. Reference lists of included studies, relevant reviews, and meta‐analyses were manually searched for additional reports.

Data Extraction and Coded Variables {#jah31718-sec-0008}
-----------------------------------

Coded variables were extracted using a standardized coding form and coder manual previously developed by a team of experts (L.S.P., B.T.J., T.B.H.M) and pilot tested. Two trained coders (H.V.M., K.C.F.) independently extracted and entered study information with high reliability across all dimensions (mean Cohen κ=0.86 for categorical variables;[35](#jah31718-bib-0035){ref-type="ref"} mean Pearson r=0.94 for continuous variables); all disagreements were resolved by discussion. Coded variables included methodological study quality and characteristics of the study, sample, and dynamic RT intervention. Only 14% of the studies[21](#jah31718-bib-0021){ref-type="ref"}, [24](#jah31718-bib-0024){ref-type="ref"}, [36](#jah31718-bib-0036){ref-type="ref"}, [37](#jah31718-bib-0037){ref-type="ref"}, [38](#jah31718-bib-0038){ref-type="ref"}, [39](#jah31718-bib-0039){ref-type="ref"}, [40](#jah31718-bib-0040){ref-type="ref"}, [41](#jah31718-bib-0041){ref-type="ref"}, [42](#jah31718-bib-0042){ref-type="ref"} disclosed the race/ethnicity of their study participants. When unreported, race/ethnicity was estimated using study location;[43](#jah31718-bib-0043){ref-type="ref"}, [44](#jah31718-bib-0044){ref-type="ref"}, [45](#jah31718-bib-0045){ref-type="ref"} samples were considered "white" for North America, Europe, and Australia; "Asian" for Asia and India; "Hispanic/Latino" for South and Central America; and "Black" for Africa. Approximately one‐third of studies failed to disclose information regarding BP medication use among their study participants. Similar estimates were observed among studies that did not report BP medication use (k=22) and those that reported no BP medication use among their sample (k=35; *P*\>0.05); therefore, these studies were combined (k=57) for subsequent moderator analyses. Chronic diseases and health conditions related to CVD were categorized based on the total number reported in the sample.[31](#jah31718-bib-0031){ref-type="ref"}, [46](#jah31718-bib-0046){ref-type="ref"} Studies that reported ≥2 chronic diseases/health conditions among their sample were categorized as having "multiple chronic conditions."[32](#jah31718-bib-0032){ref-type="ref"}, [33](#jah31718-bib-0033){ref-type="ref"}

Methodological quality of the studies in our sample was assessed using a modified version of the Downs and Black Checklist[47](#jah31718-bib-0047){ref-type="ref"}, [48](#jah31718-bib-0048){ref-type="ref"} (see Data S2 for the augmented checklist). This instrument[49](#jah31718-bib-0049){ref-type="ref"} is well validated in the health promotion literature and is reliable for assessing both RCTs and non‐RCTs.[50](#jah31718-bib-0050){ref-type="ref"} The Downs and Black checklist addresses 5 subscales of quality (ie, reporting, external validity, bias, confounding, and power) and is considered one of the most comprehensive instruments available for assessing methodological study quality.[50](#jah31718-bib-0050){ref-type="ref"} The *overall* methodological quality was gauged as percentage of items satisfied out of a possible 29‐point total and was quantified as: low (≤14 points, \<50%), moderate (\>14--23 points, 50--79%), or high (≥24 points, ≥80%).[47](#jah31718-bib-0047){ref-type="ref"}, [48](#jah31718-bib-0048){ref-type="ref"} In addition to quantifying the quality of the dynamic RT literature, we examined how *overall* methodological quality, quality subscales, and individual dimensions of quality influenced the BP response to dynamic RT *independently* and *interactively* [51](#jah31718-bib-0051){ref-type="ref"} with other moderators.

Study Outcomes and Effect‐Size Calculation {#jah31718-sec-0009}
------------------------------------------

Standardized mean difference effect size (d) was used to quantify the effectiveness of dynamic RT as stand‐alone antihypertensive therapy, defined as the mean difference in resting SBP/DBP between dynamic RT and control groups post‐ versus pre‐intervention divided by the pooled SD, correcting for small sample size bias and baseline differences.[52](#jah31718-bib-0052){ref-type="ref"}, [53](#jah31718-bib-0053){ref-type="ref"} We disaggregated comparisons for studies with \>1 dynamic RT interventions (eg, high vs low intensity RT);[42](#jah31718-bib-0042){ref-type="ref"}, [54](#jah31718-bib-0054){ref-type="ref"}, [55](#jah31718-bib-0055){ref-type="ref"}, [56](#jah31718-bib-0056){ref-type="ref"}, [57](#jah31718-bib-0057){ref-type="ref"}, [58](#jah31718-bib-0058){ref-type="ref"}, [59](#jah31718-bib-0059){ref-type="ref"} *d*s were calculated for each comparison (k) and analyzed as separate studies.[60](#jah31718-bib-0060){ref-type="ref"} Negative *d* values indicated that dynamic RT reduced BP more than the non‐exercise control group, and the magnitude of *d* values was interpreted as −0.20, −0.50, and −0.80 for small, medium and large BP reductions.[61](#jah31718-bib-0061){ref-type="ref"} Last, we provide the *unstandardized* mean effect size (ie, BP difference in mm Hg between RT and control groups at post‐ versus pre‐intervention)[60](#jah31718-bib-0060){ref-type="ref"}, [62](#jah31718-bib-0062){ref-type="ref"} as a supplement to *d* in order to enhance the clinical utility of our findings.[63](#jah31718-bib-0063){ref-type="ref"}

Inconsistencies in *d*s were estimated with the Q statistic[64](#jah31718-bib-0064){ref-type="ref"} and transformed into the I^2^ statistic and its 95% CIs.[65](#jah31718-bib-0065){ref-type="ref"}, [66](#jah31718-bib-0066){ref-type="ref"} I^2^ values range from 0% (homogeneity) to 100% (greater heterogeneity); a CI that does not include 0% indicates that the hypothesis of homogeneity is rejected, and an inference of heterogeneity is merited.[65](#jah31718-bib-0065){ref-type="ref"}, [66](#jah31718-bib-0066){ref-type="ref"}

Moderator Analyses {#jah31718-sec-0010}
------------------

Given the considerable variability in the magnitude of the BP reductions observed following exercise training (ie, 0--9 mm Hg),[4](#jah31718-bib-0004){ref-type="ref"} we examined theoretically driven, a priori study‐level moderators (ie, *effect modifiers*) related to characteristics of the study (eg, methodological study quality, BP‐focused outcome), sample (eg, baseline BP, race/ethnicity), and dynamic RT intervention (eg, the FIT, number of RT exercises) to determine what combinations elicited the greatest BP reductions. Weighted regression models (viz, meta‐regressions) with maximum‐likelihood estimation of the random‐effects weights, the inverse of the variance for each *d*, were used to explain the variability in *d*s for SBP and DBP. Continuous moderators were mean centered and categorical variables were contrast coded before generating interaction terms or performing multiple moderator analyses.[51](#jah31718-bib-0051){ref-type="ref"}, [67](#jah31718-bib-0067){ref-type="ref"}

### Multiple moderator meta‐regression models {#jah31718-sec-0011}

Because meta‐analysis is correlational in nature, we did not rely solely on individual bivariate metaregressions to "prescreen" which a priori, theoretically driven, study‐level moderators would be examined in multiple moderator models.[18](#jah31718-bib-0018){ref-type="ref"}, [51](#jah31718-bib-0051){ref-type="ref"}, [68](#jah31718-bib-0068){ref-type="ref"} In addition to identifying significant or trending (*P≤*0.10) moderators in bivariate meta‐regression, we also examined the model coefficient and *R* ^2^ value (ie, proportion of variance explained by the covariate) for individual moderators to gauge its influence on the BP response to RT.[18](#jah31718-bib-0018){ref-type="ref"}

Moderator patterns should emerge more clearly among higher‐quality studies,[69](#jah31718-bib-0069){ref-type="ref"}, [70](#jah31718-bib-0070){ref-type="ref"}, [71](#jah31718-bib-0071){ref-type="ref"} where threats to validity and other biases are minimized and potentially confounding variables are accounted for (ie, "suppression effect"[72](#jah31718-bib-0072){ref-type="ref"}).[18](#jah31718-bib-0018){ref-type="ref"}, [51](#jah31718-bib-0051){ref-type="ref"}, [68](#jah31718-bib-0068){ref-type="ref"} Because we did not exclude potentially relevant studies based on the experimental design (ie, we included both RCTs and non‐RCTs), level of evidence (ie, methodological quality), or "risk of bias," we used the "meta‐regression adjustment approach"[73](#jah31718-bib-0073){ref-type="ref"} to empirically control or adjust for possible methodological differences across RT studies.[18](#jah31718-bib-0018){ref-type="ref"}, [51](#jah31718-bib-0051){ref-type="ref"}, [68](#jah31718-bib-0068){ref-type="ref"}, [74](#jah31718-bib-0074){ref-type="ref"}, [75](#jah31718-bib-0075){ref-type="ref"} Therefore, we included *overall* methodological study quality or individual quality dimensions (eg, BP‐focused study outcome) in our multiple moderator models when feasible.

### The moving constant technique {#jah31718-sec-0012}

Although it is commonly ignored in practice,[67](#jah31718-bib-0067){ref-type="ref"} the constant (or intercept) in a meta‐regression model can be extremely valuable in demonstrating how *ds* vary at different points along the study‐level moderator variable (or variables; eg, Ferrer et al[70](#jah31718-bib-0070){ref-type="ref"} and Brown et al[69](#jah31718-bib-0069){ref-type="ref"}, [71](#jah31718-bib-0071){ref-type="ref"}), across clinic thresholds, or other practical criteria (eg, Kirsch et al[76](#jah31718-bib-0076){ref-type="ref"}). We used the moving constant technique[67](#jah31718-bib-0067){ref-type="ref"} to estimate the magnitude of weighted mean effect sizes (d~+~) and their CIs at different levels of interest for individual study‐level moderators, including extreme values and other observations, within that range. These estimates, or predicted d~+~ values (${\hat{d}}_{+}$), and their 95% CIs statistically control for the presence of each moderator in the model, held constant at their mean levels, except for the moderator and level of interest.

### Additive model {#jah31718-sec-0013}

For both SBP and DBP, an additive model was generated from the final multiple moderator model that represented the greatest *potential* antihypertensive benefit that could be achieved with dynamic RT. In this approach, individual moderators and interaction terms are evaluated simultaneously at the level (ie, ${\hat{d}}_{+}$ and 95% CIs) that confers the largest BP reductions, which in turn, identifies the combination of study‐level moderators, including sample and dynamic RT characteristics, that elicits *optimal* antihypertensive benefit.

In order to facilitate clinical interpretations, we transformed our results arithmetically to provide the equivalent BP change in mm Hg. For each moderator dimension and level of interest, we back‐converted the standardized estimate (ie, ${\hat{d}}_{+}$) into mm Hg of BP change by multiplying the predicted *d* values by the SD corresponding to the BP level of interest.[63](#jah31718-bib-0063){ref-type="ref"} Specific transformation details appear in the table footnotes.

Publication Bias {#jah31718-sec-0014}
----------------

We visually examined funnel plots for any asymmetries in the effect‐size distribution to identify potential publication or other reporting biases.[77](#jah31718-bib-0077){ref-type="ref"} We also evaluated the potential for publication bias using Begg[78](#jah31718-bib-0078){ref-type="ref"} and Egger[79](#jah31718-bib-0079){ref-type="ref"} methods; neither test suggested publication bias (*Ps\>*0.19; see Figures S1 and S2).

Sensitivity Analyses {#jah31718-sec-0015}
--------------------

To determine whether multiple treatment studies (ie, non‐independent effect sizes that result from different RT interventions being compared to a single control group)[80](#jah31718-bib-0080){ref-type="ref"} influenced our weighted mean estimates and multiple moderator meta‐regressions, we performed alternative analyses in R[81](#jah31718-bib-0081){ref-type="ref"} using the metafor package (viz, *rma.mv* function).[80](#jah31718-bib-0080){ref-type="ref"}, [82](#jah31718-bib-0082){ref-type="ref"} Multivariate meta‐analytic models, following random‐effects assumptions with maximum‐likelihood estimation that accounted for these issues, yielded the same pattern of results (see Tables S1 and S2 for the multivariate mean estimates and multiple moderator models). For simplicity of interpretation, we only report the maximum‐likelihood estimation analyses for SBP and DBP below.

Statistical Computing {#jah31718-sec-0016}
---------------------

Continuous variables are summarized as mean±SD, unless otherwise stated, and categorical variables are presented as absolute values and percentages. Differences in baseline characteristics between the dynamic RT and control groups were examined using *t*‐tests, one‐way ANOVA, and Fisher\'s exact test. Analyses used Stata software (version 13.1; StataCorp LP, College Station, TX)[83](#jah31718-bib-0083){ref-type="ref"} with macros for meta‐analysis,[60](#jah31718-bib-0060){ref-type="ref"}, [84](#jah31718-bib-0084){ref-type="ref"} incorporating random‐effects assumptions. Two‐sided statistical significance was *P*\<0.05.

Results {#jah31718-sec-0017}
=======

We identified 64 controlled studies that satisfied inclusionary criteria.[1](#jah31718-note-1002){ref-type="fn"} Seven studies involved \>1 dynamic RT groups comparing lower‐ versus higher‐intensity RT,[42](#jah31718-bib-0042){ref-type="ref"}, [57](#jah31718-bib-0057){ref-type="ref"}, [58](#jah31718-bib-0058){ref-type="ref"}, [59](#jah31718-bib-0059){ref-type="ref"} strength versus power RT,[55](#jah31718-bib-0055){ref-type="ref"} elastic band versus aquatic RT,[54](#jah31718-bib-0054){ref-type="ref"} and eccentric versus concentric RT,[56](#jah31718-bib-0056){ref-type="ref"} yielding 71 *total* interventions. [Figure](#jah31718-fig-0001){ref-type="fig"} shows the systematic search for potential reports and selection process of included dynamic RT studies.

![Flow chart detailing the systematic search of potential reports (n) and selection process of included dynamic resistance training studies. AET indicates aerobic exercise training; BP, blood pressure; CINAHL, cumulative index to nursing and allied health literature; CET, concurrent exercise training; FITT, Frequency, Intensity, Time and Type; RT, resistance training.](JAH3-5-e003231-g001){#jah31718-fig-0001}

Study Characteristics {#jah31718-sec-0018}
---------------------

Table S3 provides a general description of each study, sample, and intervention characteristics for the dynamic RT and control groups. Included RT studies were published between 1987 and 2013, the majority were RCTs (82%), and approximately half examined BP as a primary study outcome (48%). Most interventions involved a non‐exercise/wait‐listed control group (86%); 9 studies involved a "placebo" control/comparison group[2](#jah31718-note-1003){ref-type="fn"} (Table S3).

Included studies achieved "moderate" methodological study quality (≈63%),[47](#jah31718-bib-0047){ref-type="ref"}, [48](#jah31718-bib-0048){ref-type="ref"} despite widely varying scores (41--85%; see Table S4). Studies were most likely to satisfy reporting (78.6%) and internal validity (bias=70.2% and confounding=51.5%) quality subscales, but least likely to satisfy external validity (46.5%) and power (9.2%). None of the subscales emerged as significant moderators in analyses; only 7 studies satisfied ≥80% of quality items (≈83.3%; see Table S5 for the overall and itemized summary of methodological study quality for each intervention).

Sample Characteristics {#jah31718-sec-0019}
----------------------

Table [1](#jah31718-tbl-0001){ref-type="table-wrap"} summarizes baseline sample characteristics for the RT and control groups. The dynamic RT (total N across samples*=*1305) and control (N=1039) samples were sedentary,[130](#jah31718-bib-0130){ref-type="ref"} middle‐aged (47.4±19.0 years), overweight (26.7±3.5 kg/m^2^) adults with prehypertension (SBP/DBP: 126.4±9.4/76.6±8.4 mm Hg).[131](#jah31718-bib-0131){ref-type="ref"} Approximately 15% of the total sample was on antihypertensive medication (N=349), but one‐third of studies did not disclose this information (≈68% did). The majority of RT studies (≈60%) involved adults without CVD‐related chronic diseases or health conditions other than their high BP (N=1286). A small subset of RT studies included participants with known CVD‐related chronic diseases (3 studies; N=64),[55](#jah31718-bib-0055){ref-type="ref"}, [86](#jah31718-bib-0086){ref-type="ref"}, [103](#jah31718-bib-0103){ref-type="ref"} or CVD risk factors other than hypertension (7 studies; N=161);[36](#jah31718-bib-0036){ref-type="ref"}, [55](#jah31718-bib-0055){ref-type="ref"}, [90](#jah31718-bib-0090){ref-type="ref"}, [91](#jah31718-bib-0091){ref-type="ref"}, [101](#jah31718-bib-0101){ref-type="ref"}, [114](#jah31718-bib-0114){ref-type="ref"}, [118](#jah31718-bib-0118){ref-type="ref"} 11 studies (17.2%) reported a clustering of ≥2 chronic diseases and/or health conditions among their sample (see Tables [1](#jah31718-tbl-0001){ref-type="table-wrap"} and S3).

###### 

Baseline Sample Characteristics for the Dynamic RT (k=71) and Control (k=63) Intervention Groups

  Characteristic                                                                                                     k    Dynamic RT (n=1305)   k    Control (n=1039)
  ------------------------------------------------------------------------------------------------------------------ ---- --------------------- ---- ------------------
  Women, n (%)                                                                                                       69   622 (47.7)            61   477 (45.9)
  Age, y                                                                                                             68   47.2±19.0             61   47.2±19.1
  Race/ethnicity, n (%)                                                                                              71                         63   
  White                                                                                                              40   775 (59.4)            36   554 (53.3)
  Asian                                                                                                              17   263 (20.2)            14   227 (21.8)
  Hispanic/Latino/Caribbean                                                                                          13   254 (19.5)            12   243 (23.4)
  Black/African American                                                                                             1    13 (1.0)              1    15 (1.4)
  Sedentary, n (%)[a](#jah31718-note-0003){ref-type="fn"}                                                            53   926 (71.0)            47   764 (73.5)
  BP medication, n (% using)                                                                                         49   177 (13.6)            42   172 (16.5)
  BP classification, n (%)[b](#jah31718-note-0004){ref-type="fn"}                                                                                    
  Normal                                                                                                             16   242 (18.5)            12   164 (15.8)
  Prehypertension                                                                                                    41   688 (52.7)            41   587 (56.5)
  Hypertension                                                                                                       14   375 (28.7)            10   292 (28.1)
  Health status, n (%)                                                                                               65                         54   
  No CVD‐related chronic conditions[c](#jah31718-note-0005){ref-type="fn"}                                           38   611 (46.8)            33   446 (42.9)
  CVD‐related chronic conditions[d](#jah31718-note-0006){ref-type="fn"}                                              27   499 (38.2)            21   380 (36.6)
  1 chronic disease/health condition[e](#jah31718-note-0007){ref-type="fn"}                                          16   280 (21.5)            11   158 (15.2)
  2 to 3 chronic diseases/health conditions[f](#jah31718-note-0008){ref-type="fn"}                                   7    69 (5.3)              6    68 (6.5)
  ≥4 chronic diseases/health conditions[f](#jah31718-note-0008){ref-type="fn"}                                       4    150 (11.5)            4    154 (14.8)
  Chronic conditions reported per sample                                                                                  1.9±1.3                    2.0±1.3
  Body composition                                                                                                                                   
  Body weight, kg                                                                                                    61   75.0±11.7             59   74.1±12.0
  BMI, kg/m^2^                                                                                                       60   26.8±3.4              58   26.6±3.7
  Waist circumference, cm                                                                                            17   96.9±9.3              17   96.1±10.0
  Body fat (%)                                                                                                       36   29.7±6.9              36   29.3±7.9
  Fat mass, kg                                                                                                       11   26.4±6.8              11   26.7±7.2
  Lean mass, kg                                                                                                      20   50.9±11.2             20   49.4±11.1
  Resting hemodynamics                                                                                                                               
  Systolic BP, mm Hg                                                                                                 71   126.7±10.3            70   126.3±9.4
  Diastolic BP, mm Hg                                                                                                71   76.8±8.7              70   76.5±8.6
  Mean arterial pressure, mm Hg                                                                                      71   93.2±8.0              70   93.2±8.2
  Pulse pressure, mm Hg                                                                                              71   49.4±8.3              70   49.8±6.8
  Heart rate, beats/min                                                                                              41   70.1±6.9              40   69.1±7.3
  Strength and fitness measures[g](#jah31718-note-0009){ref-type="fn"} ^,^ [h](#jah31718-note-0010){ref-type="fn"}                                   
  Upper body strength, kg                                                                                            18   44.5±31.3             10   43.4±36.5
  Lower body strength, kg                                                                                            24   92.3±58.8             16   97.3±69.7
  Cardiorespiratory fitness, mL/kg per minutes                                                                       24   28.6±9.9              23   29.7±9.4

Statistics are summarized as mean±SD, or the number of participants and proportion of the total RT and control samples, n (%). BMI indicates body mass index; BP, blood pressure; CVD, cardiovascular disease; k, number of observations; RT, resistance training.

Participation in \<30 minutes of moderate intensity, physical activity on ≤2 days/week;[130](#jah31718-bib-0130){ref-type="ref"} in the absence of physical activity data, samples that were reported as "sedentary" were also included.

BP classification published in the Seventh Report of the Joint National Committee.[131](#jah31718-bib-0131){ref-type="ref"}

Samples were free from CVD‐related chronic diseases or health conditions.

Studies that reported CVD‐related chronic diseases or health conditions among subjects (or medications used to treat diseases/conditions) were categorized based on the total number reported in their sample (ie, 1, 2 to 3, or ≥4; ranging from 1 to 5).[31](#jah31718-bib-0031){ref-type="ref"}, [46](#jah31718-bib-0046){ref-type="ref"}

Chronic diseases/health conditions[130](#jah31718-bib-0130){ref-type="ref"} were not mutually exclusive (ie, subjects could have 1 or more); health conditions included hypertension, metabolic syndrome (MetS), and obesity, dyslipidemia (ie, CVD risk factors); chronic diseases: type 2 diabetes mellitus (T2DM), chronic heart failure, and nonalcoholic fatty liver disease (ie, CVD or metabolic diseases).

The most commonly reported combinations included: hypertension, MetS, or dyslipidemia with T2DM (see Table S5 for individual study details).

Upper/lower body strength was reported for 25 of 33 RT and 14 of 24 control groups, respectively; only those reported in kilograms (kg) are summarized.

Baseline fitness was reported for 37 RT and 36 control groups; only relative oxygen uptake assessed by peak or maximal tests are summarized.

Of the 9 studies that reported race/ethnicity (N=446), 6 included all[37](#jah31718-bib-0037){ref-type="ref"} or predominantly (80--96%)[36](#jah31718-bib-0036){ref-type="ref"}, [40](#jah31718-bib-0040){ref-type="ref"}, [41](#jah31718-bib-0041){ref-type="ref"}, [42](#jah31718-bib-0042){ref-type="ref"} white participants (N=274), 3[24](#jah31718-bib-0024){ref-type="ref"}, [38](#jah31718-bib-0038){ref-type="ref"}, [39](#jah31718-bib-0039){ref-type="ref"} included Hispanic/Latino and/or Caribbean participants (N=137), 2 studies[36](#jah31718-bib-0036){ref-type="ref"}, [41](#jah31718-bib-0041){ref-type="ref"} included a small proportion of African American/Black participants (N=9), and 5[21](#jah31718-bib-0021){ref-type="ref"}, [36](#jah31718-bib-0036){ref-type="ref"}, [40](#jah31718-bib-0040){ref-type="ref"}, [42](#jah31718-bib-0042){ref-type="ref"} included "other" participants (N=25; Table S3). When we combined the reported *and* estimated race/ethnicity determinations, the included studies yielded a diverse sample that consisted of 56.7% white (N=1329) and 43.3% non‐white samples (N=1015), that is, 21.2% Hispanic/Latino (N=497), 20.9% Asian (N=490), and 1.2% Black (N=28). Baseline sample characteristics were similar between the dynamic RT and control groups (Table [1](#jah31718-tbl-0001){ref-type="table-wrap"}).

Dynamic RT Intervention Characteristics {#jah31718-sec-0020}
---------------------------------------

Table [2](#jah31718-tbl-0002){ref-type="table-wrap"} summarizes the features of the RT interventions. Dynamic RT was performed 2.8±0.6 days/week for 14.4±7.9 weeks using moderate loads/intensity that corresponded to 65% to 70% of 1 repetition maximum (1‐RM), averaging 64.7±13.0% of 1‐RM. RT programs generally targeted the whole body (91%), but varied widely in their prescription of other acute program variables (eg, RT protocols consisted of 1--5 sets/exercise of 5--30 repetitions/set for 1--16 RT exercises/session; Table [2](#jah31718-tbl-0002){ref-type="table-wrap"}). On average, dynamic RT programs prescribed 2.8±0.9 sets of 11.0±3.8 repetitions for 7.9±2.9 dynamic RT exercises per session. One‐fourth of studies (27%) failed to disclose the level of supervision during the dynamic RT intervention; of those that did, 63% reported direct supervision. The overall adherence to dynamic RT was high (92.3%±8.9%), but adherence was only reported in 65% of the studies.

###### 

Summary of Dynamic RT Intervention Characteristics (k*=*71)

  Program Characteristics                                         k    Mean±SD     Range         Median
  --------------------------------------------------------------- ---- ----------- ------------- --------
  Participants (n) at baseline                                    71   21.1±14.9   8.0, 72.0     15.0
  Participants (n) post‐RT                                        71   18.4±11.4   8.0, 60.0     14.0
  Attrition in RT group (%)                                       71   8.5±13.1    0.0, 53.0     0.0
  Exercise adherence (%)                                          46   92.3±8.9    60.0, 100.0   95.0
  Dynamic RT FITT                                                                                
  Length (weeks)                                                  71   14.4±7.9    6.0, 48.0     12.0
  Frequency (days/week)                                           71   2.8±0.6     2.0, 5.0      3.0
  Intensity or Load                                                                              
  \% of 1‐RM                                                      38   64.7±13.0   30.0, 87.5    65.0
  \% of MVC                                                       2    90.0±14.4   80.0, 100.0   
  10 to 15 RM                                                     8    12.6%                     
  8 to 12 RM                                                      8    12.5%                     
  6 to 16 RM                                                      2    3.1%                      
  OMNI‐RT Scale                                                   2    3.1%                      
  Theraband (not specified)                                       3    4.7%                      
  \% of 1‐RM (estimated)[a](#jah31718-note-0012){ref-type="fn"}   63   67.2±12.4   30.0, 100.0   70.0
  MET (estimated)[b](#jah31718-note-0013){ref-type="fn"}          71   4.7±1.8     2.8, 8.5      3.8
  Time (total work/session)                                                                      
  Number of exercises/session                                     69   7.9±2.9     1.0, 16.0     7.0
  Number sets/exercise                                            67   2.8±0.9     1.0, 5.0      3.0
  Number repetitions/set                                          65   11.0±3.8    5.0, 30.0     10.0
  Rest interval/recovery (s)                                      30   96.3±43.3   15.0, 180.0   90.0
  Type of RT protocol                                                                            
  Conventional RT                                                 54   76.0%                     
  Circuit‐style RT                                                10   14.3%                     
  Theraband                                                       4    5.7%                      
  Ankle or shin weights                                           2    2.9%                      
  Muscle groups targeted                                                                         
  Upper and lower body                                            63   91.3%                     
  Lower body                                                      4    5.8%                      
  Unilateral, upper body                                          2    2.9%                      

\% indicates percentage; FITT, frequency, intensity, time, and type; k, number of observations; MET, metabolic equivalent unit; MVC, maximum voluntary contraction; Range, minimum, maximum values; Reps, repetitions; RM, repetition maximum; RT, resistance training; s, seconds.

\% of 1‐RM was estimated for studies that reported RT intensity/load as 1‐RM range or MVC (%); represents the mean 1‐RM (%) after combining the estimated and reported values (k=38).

Standardized estimate of RT intensity/load; METs were assigned to all RT interventions so that RT intensity/loads could be quantified across studies, including unreported data (k*=*12) and units other than 1‐RM or MVC (k=39).

Resting BP Assessment {#jah31718-sec-0021}
---------------------

Most interventions reported the instrument used to assess BP (81.7%), with BP most commonly measured in the seated (42.3%) or supine (26.8%) position. Yet, ≈69% of the dynamic RT interventions did not report these details (see Table S6).

Dynamic RT as Stand‐Alone Antihypertensive Therapy {#jah31718-sec-0022}
--------------------------------------------------

Small‐to‐moderate reductions in SBP (d~+~ *=*−0.31; 95% CI, −0.43, −0.19; −3.0 mm Hg) and DBP (d~+~=−0.30; 95% CI, −0.38, −0.18; −2.1 mm Hg) were observed following dynamic RT versus control, although effect sizes for SBP (I^2^=51%; 95% CI, 36--63%) and DBP (I^2^=35%; 95% CI, 13--52%) lacked homogeneity (see Figure S3 for contour‐enhanced funnel plots, a visual display of the effect‐size distribution). Table S7 summarizes the weighted mean effect size and tests for homogeneity for the control, dynamic RT, and dynamic RT versus control.

Moderator Analyses: Multiple Moderator Models {#jah31718-sec-0023}
---------------------------------------------

### Multiple moderator SBP model {#jah31718-sec-0024}

SBP reductions were greater among studies involving samples with higher resting SBP (*P*=0.011), which occurred in a dose‐response fashion: 5.7 mm Hg for samples with hypertension, 3.0 mm Hg for samples with prehypertension, and 0.0 mm Hg for samples with normal BP. SBP was also reduced to a greater extent among studies involving non‐white than white samples (*P*=0.002), and among study samples that were not taking BP medication versus those that were (*P*=0.034). Greater SBP reductions occurred among studies that prescribed ≥8 versus \<8 dynamic RT exercises/session (*P*=0.043), and among studies that examined BP as a primary outcome versus those that did not (*P*=0.032; Table [3](#jah31718-tbl-0003){ref-type="table-wrap"}). Collectively, these study‐level moderators accounted for ≈67% of the variance in the BP response to dynamic RT.

###### 

Multiple Moderator Model: SBP Response to Dynamic RT (k=69)[a](#jah31718-note-0015){ref-type="fn"}

  Moderator Dimension/Level                                                  ${\hat{d}}_{+}$ (95% CI)[b](#jah31718-note-0016){ref-type="fn"}   β                      *P* Value   SBP ∆ (mm Hg)[c](#jah31718-note-0017){ref-type="fn"}                                                   
  -------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------- ----------- ------------------------------------------------------------------------------------------------------ ---------------------
  Resting SBP of RT sample, mm Hg                                                                                                              −0.311                 0.011                                                                                                              
  Normal=115±11 (k*=*16)                                                     0.00 (−0.23, 0.23)                                                                                   0.0 (−2.5, 2.5)                                                                                        
  Prehypertension=130±13 (k*=*41)                                            −0.23 (−0.39, −0.07)                                                                                 −3.0 (−5.1, −1.0)[d](#jah31718-note-0018){ref-type="fn"}                                               
  Hypertension=142±14 (k*=*14)[f](#jah31718-note-0020){ref-type="fn"}        −0.41 (−0.64, −0.19)                                                                                 −5.7 (−9.0, −2.7)[d](#jah31718-note-0018){ref-type="fn"} ^,^ [e](#jah31718-note-0019){ref-type="fn"}   
  Race/ethnicity of RT sample                                                                                                                  0.354                  0.002                                                                                                              
  White samples (k*=*40)                                                     −0.00 (−0.20, 0.20)                                                                                  0.0 (−2.6, 2.6)                                                                                        
  Nonwhite samples (k*=*31)[f](#jah31718-note-0020){ref-type="fn"}           −0.36 (−0.56, −0.16)                                                                                 −4.7 (−7.3, −2.1)[d](#jah31718-note-0018){ref-type="fn"}                                               
  BP medication use of RT sample                                                                                                               0.261                  0.034                                                                                                              
  Taking BP medication (k*=*14)                                              −0.03 (−0.29, 0.23)                                                                                  −0.4 (−3.8, 3.0)                                                                                       
  Not taking BP medication (k*=*57)[f](#jah31718-note-0020){ref-type="fn"}   −0.33 (−0.48, −0.17)                                                                                 −4.3 (−6.2, −2.2)[d](#jah31718-note-0018){ref-type="fn"}                                               
  RT exercises performed/session                                                                                                               −0.221                 0.043                                                                                                              
  \<8 RT exercises=6 (k*=*37)                                                −0.11 (−0.29, 0.08)                                                                                  −1.4 (−4.4, 1.0)                                                                                       
  ≥8 RT exercises=12 (k*=*32)[f](#jah31718-note-0020){ref-type="fn"}         −0.34 (−0.55, −0.12)                                                                                 −4.4 (−7.2, −1.6)[d](#jah31718-note-0018){ref-type="fn"}                                               
  Primary study outcome                                                                                                                        −0.238                 0.032                                                                                                              
  BP focused outcome (k*=*34)[f](#jah31718-note-0020){ref-type="fn"}         −0.30 (−0.49, −0.10)                                                                                 −3.9 (−6.4, −1.3)[d](#jah31718-note-0018){ref-type="fn"}                                               
  Non‐BP focused outcome (k*=*37)                                            −0.06 (−0.26, 0.14)                                                                                  −0.8 (−3.4, 1.8)                                                                                       
  Additive SBP model[f](#jah31718-note-0020){ref-type="fn"}                  Non‐white samples                                                 −1.02 (−1.36, −0.67)                                                                                                                      −14.3 (−19.0, −9.4)
  White samples                                                              −0.66 (−0.97, −0.35)                                                                                 −9.2 (−13.6, −4.9)                                                                                     

Resting SBP is presented as mean±SD. ∆ indicates change; BP, blood pressure; k, number of observations; RT, resistance training; SBP, systolic BP; β, standardized coefficient represents unique variance explained by moderator.

Multiple *R* ^2^ (variance explained by model, adjusted for number of moderators)=67.1%; I^2^ residual (variance unexplained by model)=27.3%.

Predicted weighted mean effect size (d~+~); estimate of the magnitude of SBP reduction among the RT group relative to control, while statistically controlling for the presence of each moderator shown in the above model (held constant at their mean), except for moderator/level of interest. This model also controls for (not shown): 1 versus 2 RT groups (β=−0.235; *P*=0.050) and SBP×RT exercises interaction (β=0.174; *P*=0.133).

SBP ∆=${\hat{d}}_{+}$ (95% CIs) back‐converted to mm Hg. For each moderator/level of interest, ${\hat{d}}_{+}$ (95% CIs) were transformed arithmetically using the SD corresponding to the sample mean (130±13 mm Hg): ∆=${\hat{d}}_{+}$ (95% CI)×13 mm Hg, with the exception of normal SBP: ∆=${\hat{d}}_{+}$ (95% CI)×11 mm Hg; hypertension SBP and additive SBP model: ∆=${\hat{d}}_{+}$ (95% CI)×14 mm Hg.

(*P\<*0.05): normal SBP; white samples; taking medication; 6 exercises; non‐BP outcome.

Normal and prehypertension SBP.

Indicates the moderator dimensions/levels that conferred the largest SBP reductions and were used to generate the additive SBP model.

### Additive SBP model {#jah31718-sec-0025}

Dynamic RT elicited the greatest *potential* SBP benefit among studies that included samples with untreated hypertension and prescribed ≥8 dynamic RT exercises/session (−11.8 mm Hg; 95% CI, −16.0, −7.4), an effect that was significantly greater among studies involving non‐white than white samples (see [additive SBP model](#jah31718-sec-0025){ref-type="sec"}, bottom of Table [3](#jah31718-tbl-0003){ref-type="table-wrap"}).

### Multiple moderator DBP model {#jah31718-sec-0026}

DBP reductions were greater among studies involving samples with higher resting DBP (*P*=0.023): 5.2 mm Hg for samples with hypertension, 3.3 mm Hg for samples with prehypertension, and 1.0 mm Hg for samples with normal BP, and among study samples not taking BP medications versus those that were (*P*=0.028). Greater DBP reductions occurred among studies that prescribed dynamic RT ≥3 versus \<3 days/week (*P*=0.02), and among studies that achieved lower than higher methodological study quality (*P*=0.019; Table [4](#jah31718-tbl-0004){ref-type="table-wrap"}). Collectively, these study‐level moderators accounted for ≈50% of the variance in the BP response to dynamic RT.

###### 

Multiple Moderator Model: DBP Response to Dynamic RT (k=71)[a](#jah31718-note-0022){ref-type="fn"}

  Moderator Dimension/Level                                                     ${\hat{d}}_{+}$ (95% CI)[b](#jah31718-note-0023){ref-type="fn"}   β                      *P* Value   DBP ∆ (mm Hg)[c](#jah31718-note-0024){ref-type="fn"}       
  ----------------------------------------------------------------------------- ----------------------------------------------------------------- ---------------------- ----------- ---------------------------------------------------------- ---------------------
  Resting DBP of RT sample, mm Hg                                                                                                                 −0.317                 0.023                                                                  
  Normal=69±7 (k*=*16)                                                          −0.13 (−0.30, 0.31)                                                                                  −0.9 (−2.1, 2.2)                                           
  Prehypertension=83±9 (k*=*41)                                                 −0.37 (−0.59, −0.15)                                                                                 −3.3 (−5.3, −1.4)[d](#jah31718-note-0025){ref-type="fn"}   
  Hypertension=92±10 (k*=*14)[f](#jah31718-note-0027){ref-type="fn"}            −0.52 (−0.84, −0.19)                                                                                 −5.2 (−8.4, −1.9)[d](#jah31718-note-0025){ref-type="fn"}   
  BP medication use of RT sample                                                                                                                  0.260                  0.028                                                                  
  Currently taking BP medication (k*=*14)                                       −0.13 (−0.38, 0.11)                                                                                  −1.2 (−3.4, 1.0)                                           
  Not taking BP medication (k*=*57)[f](#jah31718-note-0027){ref-type="fn"}      −0.39 (−0.55, −0.23)                                                                                 −3.5 (−5.0, −2.1)[d](#jah31718-note-0025){ref-type="fn"}   
  Frequency of RT sessions                                                                                                                        −0.262                 0.020                                                                  
  \<3 days=2 days weekly (k*=*22)                                               −0.10 (−0.31, 0.11)                                                                                  −0.9 (−2.8, 1.0)                                           
  ≥3 days=4 days weekly (k*=*49)[f](#jah31718-note-0027){ref-type="fn"}         −0.50 (−0.76, −0.23)                                                                                 −4.5 (−6.8, −2.1)[d](#jah31718-note-0025){ref-type="fn"}   
  Methodological study quality                                                                                                                    0.296                  0.019                                                                  
  Lower quality=49% satisfied (k*=*25)[f](#jah31718-note-0027){ref-type="fn"}   −0.41 (−0.62, −0.19)                                                                                 −3.7 (−5.6, −1.7)[e](#jah31718-note-0026){ref-type="fn"}   
  Moderate quality=63% satisfied (k*=*35)                                       −0.20 (−0.38, −0.03)                                                                                 −1.8 (−3.4, −0.3)[d](#jah31718-note-0025){ref-type="fn"}   
  Higher quality=82% satisfied (k*=*11)                                         −0.03 (−0.28, 0.22)                                                                                  −0.3 (−2.5, 2.0)                                           
  Additive DBP model[f](#jah31718-note-0027){ref-type="fn"}                     Non‐white samples                                                 −1.03 (−1.45, −0.62)                                                                          −10.3 (−14.5, −6.2)
  White samples                                                                 −0.95 (−1.35, −0.54)                                                                                 −9.5 (−13.5, −5.2)                                         

Resting DBP is presented as mean±SD. ∆ indicates change; BP, blood pressure; DBP, diastolic blood pressure; k, number of observations; RT, resistance training; β, standardized coefficient represents unique variance explained by moderator.

Multiple *R* ^2^ (variance explained by model, adjusted for number of moderators)=49.9%; I^2^ residual (variance unexplained by model)=19.6%.

Predicted weighted mean effect size (d~+~); estimate of the magnitude of DBP reduction among the RT group relative to control, while statistically controlling for the presence of each moderator shown in the above model (held constant at their mean), except for the moderator/level of interest. This model also controls for (not shown): race/ethnicity (β=0.097; *P*=0.382), 1 versus 2 RT groups (β=−0.017; *P*=0.902), and DBP×RT groups interaction (β=0.248; *P*=0.056).

DBP ∆=${\hat{d}}_{+}$ (95% CIs) back‐converted to mm Hg. For each moderator/level of interest, ${\hat{d}}_{+}$ (95% CIs) were transformed arithmetically using the SD corresponding to the sample mean (83±9 mm Hg): ∆=${\hat{d}}_{+}$ (95% CI)×9 mm Hg, with the exception of normal DBP: ∆=${\hat{d}}_{+}$ (95% CI)×8 mm Hg; hypertension DBP and additive DBP model: ∆=${\hat{d}}_{+}$ (95% CI)×10 mm Hg.

(*P*\<0.05): normal DBP; taking medication; 2 days/week; higher quality.

Moderate and higher quality.

Indicates the moderator dimensions/levels that conferred the largest DBP reductions and were used to generate the additive DBP model.

### Additive DBP model {#jah31718-sec-0027}

Dynamic RT elicited the greatest *potential* DBP benefit among studies that included samples with untreated hypertension and prescribed dynamic RT ≥3 days/week (−9.9 mm Hg; 95% CI, −13.9, −5.9), an effect that was slightly more pronounced among studies involving non‐white than white samples (see [additive DBP model](#jah31718-sec-0027){ref-type="sec"}, bottom of Table [4](#jah31718-tbl-0004){ref-type="table-wrap"}).

Discussion {#jah31718-sec-0028}
==========

Our meta‐analysis aimed to determine the efficacy of dynamic RT as stand‐alone antihypertensive therapy and identify potential moderators of BP response to provide insight into the optimal dose of dynamic RT to lower BP among adult populations with high BP. Consistent with past meta‐analyses,[5](#jah31718-bib-0005){ref-type="ref"}, [8](#jah31718-bib-0008){ref-type="ref"}, [9](#jah31718-bib-0009){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [12](#jah31718-bib-0012){ref-type="ref"} we found that moderate‐intensity dynamic RT, on average, reduced BP ≈2 to 3 mm Hg compared to control (*Ps\<*0.001). Importantly, our moderator analyses revealed new study‐level findings that merit further comment.

Our meta‐analysis revealed that dynamic RT can elicit BP reductions that are comparable to, and in some cases greater than, those that have been previously reported with AE among study samples with hypertension.[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} Notably, we found that BP reductions following dynamic RT occurred in dose‐response fashion, such that studies involving samples with hypertension yielded the largest BP reductions (≈6/5 mm Hg), followed by samples with prehypertension (≈3/3 mm Hg), and then samples with normal BP (≈0/1 mm Hg; *Ps*≤0.023). Furthermore, studies involving non‐white (ie, Hispanic/Latino and Asian) samples with hypertension experienced even larger BP reductions that were approximately double the magnitude reportedly achieved with AE (≈10--14 vs 5--7 mm Hg).[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} Our findings should be confirmed using participant‐level data and investigated further in primary‐level studies. Nonetheless, they suggest that the present exercise recommendations for hypertension should be revisited to include dynamic RT *in addition to* AE as stand‐alone antihypertensive lifestyle therapy.

Our results add other new information to the literature by identifying clinically important study‐level moderators of BP response to dynamic RT. One of our most noteworthy findings was that dynamic RT elicited BP reductions in dose‐response fashion, which aligns with reports for AE training,[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"} but conflicts with other aggregate‐level meta‐analyses examining the BP response to dynamic RT. Reasons for the differences between our meta‐analysis and others are not completely clear, but may reside in the fact that we performed one of the largest and most comprehensive electronic searches to date, included RCT and non‐RCTs, identified 3 times the number of dynamic RT studies that involved adults with high BP (51 studies; N=1968) than previously reported (16 studies; N=617)[12](#jah31718-bib-0012){ref-type="ref"} and adhered to high‐quality, contemporary standards.[3](#jah31718-bib-0003){ref-type="ref"}, [13](#jah31718-bib-0013){ref-type="ref"}, [14](#jah31718-bib-0014){ref-type="ref"}, [15](#jah31718-bib-0015){ref-type="ref"}

Another important distinction between ours and previously published meta‐analyses[7](#jah31718-bib-0007){ref-type="ref"}, [8](#jah31718-bib-0008){ref-type="ref"}, [9](#jah31718-bib-0009){ref-type="ref"}, [10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"}, [12](#jah31718-bib-0012){ref-type="ref"} is that we applied less common, but more sophisticated, contemporary approaches, such as multiple moderator meta‐regressions,[16](#jah31718-bib-0016){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"}, [19](#jah31718-bib-0019){ref-type="ref"} interactive modeling strategies,[51](#jah31718-bib-0051){ref-type="ref"} and the moving constant technique.[67](#jah31718-bib-0067){ref-type="ref"} In contrast, past meta‐analyses have almost exclusively used subgroup or univariate meta‐regression analyses to investigate potential study‐level moderators. These 2 approaches consider moderators *individually* rather than *collectively*,[16](#jah31718-bib-0016){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"}, [19](#jah31718-bib-0019){ref-type="ref"} which is problematic not only because meta‐analysis is correlational in nature,[16](#jah31718-bib-0016){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"} but also because the BP response to exercise is complex and is likely influenced by many factors at both the study and individual level.[130](#jah31718-bib-0130){ref-type="ref"} Assessing multiple study‐level moderators in a single meta‐regression model is the preferred method because it allows sample, RT intervention, and study‐quality moderators that explain unique variance in the BP response to exercise to be isolated with greater precision and confidence.[16](#jah31718-bib-0016){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"}, [19](#jah31718-bib-0019){ref-type="ref"}, [51](#jah31718-bib-0051){ref-type="ref"}, [68](#jah31718-bib-0068){ref-type="ref"} Furthermore, the use of contemporary strategies, in particular the moving constant technique,[67](#jah31718-bib-0067){ref-type="ref"} can estimate the magnitude of BP reduction at different levels of individual moderators, thus providing more precise estimates that can facilitate interpretation of their clinical significance.

Our meta‐analysis is the first in the exercise and BP literature to incorporate methodological study quality *quantitatively* to determine whether it independently[3](#jah31718-bib-0003){ref-type="ref"}, [13](#jah31718-bib-0013){ref-type="ref"} or interactively[51](#jah31718-bib-0051){ref-type="ref"} modulates the BP response to dynamic RT. We found that BP reductions were greater among studies that achieved lower than higher methodological quality, although there was a paucity of higher‐quality dynamic RT studies in this literature, with only 7 satisfying ≥80% of quality items. We also found that, despite overall quality, greater BP reductions occurred among studies that examined BP as a primary outcome.

We, along with past meta‐analyses,[10](#jah31718-bib-0010){ref-type="ref"}, [11](#jah31718-bib-0011){ref-type="ref"}, [12](#jah31718-bib-0012){ref-type="ref"} have found this literature to be of "fair‐to‐moderate" methodological study quality.[47](#jah31718-bib-0047){ref-type="ref"}, [48](#jah31718-bib-0048){ref-type="ref"} In the absence of a higher‐quality literature, there is the potential risk of bias or other threats to validity. Therefore, in addition to assessing and controlling for methodological study quality and whether studies had BP‐focused outcomes in our multiple moderator models, we examined other sources of potential bias. We found that higher methodological quality was associated with more‐recent studies (*r=*0.45; *P*\<0.001), RCTs (*r*=0.23; *P*=0.052), studies that were adequately powered to detect BP outcomes (*r*=0.41; *P*\<0.001), involved 1 dynamic RT intervention (vs multiple; *r*=0.22; *P*=0.069), and followed established BP assessment protocols (*r*=0.24; *P*=0.045). Despite their association with methodological study quality, none of these potential biases modulated the BP response to dynamic RT. Nonetheless, they were incorporated in analyses, when feasible, to control for confounding or suppression effects that could arise from lower‐quality studies.[3](#jah31718-bib-0003){ref-type="ref"}, [51](#jah31718-bib-0051){ref-type="ref"} By examining the potential risk of bias from several sources and incorporating them into our multiple moderator models, we can be more confident in our results, despite the number of methodological deficits and inconsistencies in this literature.[51](#jah31718-bib-0051){ref-type="ref"}

Our moderator analyses also addressed other important gaps in this literature. No meta‐analysis conducted to date, until ours, has identified features of the dynamic RT intervention that influences the BP response to dynamic RT. We found that dynamic RT protocols performed, on average, 3 days/week using low‐to‐moderate loads/intensity (≈60--65% 1‐RM), consisting of 3 sets of 10 to 12 repetitions for ≈8 (3--4 upper and 4--5 lower body) exercises significantly reduced resting BP ≈5 to 6 mm Hg among studies that included samples with hypertension. We observed even larger BP reductions among studies that prescribed dynamic RT ≥3 versus \<3 days/week and ≥8 versus \<8 RT exercises/session. Our findings are in agreement with the current exercise recommendations for hypertension, and provide some of the first study‐level evidence regarding the FIT components of the dynamic RT prescription for adult populations with high BP. Nonetheless, important characteristics of the dynamic RT intervention (eg, progression, load/intensity, rest/recovery duration) were inconsistently or poorly reported. Therefore, the dynamic RT protocol that elicits the most favorable BP benefits for adult populations with hypertension remains elusive.

We also identified study‐level sample characteristics that suggests there may be particular populations that could benefit the most from dynamic RT as stand‐alone antihypertensive therapy. Namely, BP reductions were greater among study samples that were not taking antihypertensive medications compared to those that were (≈4 vs 1 mm Hg), independent of baseline BP. This finding is potentially promising because of the synergistic effect between antihypertensive medication and the magnitude of BP reductions following dynamic RT that have been reported by some,[25](#jah31718-bib-0025){ref-type="ref"}, [132](#jah31718-bib-0132){ref-type="ref"}, [133](#jah31718-bib-0133){ref-type="ref"} but not all, studies.[22](#jah31718-bib-0022){ref-type="ref"}, [121](#jah31718-bib-0121){ref-type="ref"}, [122](#jah31718-bib-0122){ref-type="ref"} Nonetheless, these findings should be interpreted with caution given the small proportion of dynamic RT studies that reported antihypertensive medication use in their sample (≈15%), and the generally poor reporting of medication use in this literature (unreported by ≈33%).

Interestingly, we found that dynamic RT studies involving non‐white (ie, Asian, Hispanic/Latino, and Black) samples with hypertension elicited BP reductions of 10 to 14 mm Hg, approximately double the magnitude that has been previously reported to occur as a result of AE training among predominately white populations (ie, 5--7 mm Hg).[3](#jah31718-bib-0003){ref-type="ref"}, [4](#jah31718-bib-0004){ref-type="ref"}, [5](#jah31718-bib-0005){ref-type="ref"}, [6](#jah31718-bib-0006){ref-type="ref"} To the best of our knowledge, only 1 meta‐analysis[43](#jah31718-bib-0043){ref-type="ref"} has investigated the potential impact of race/ethnicity on the BP response to exercise training. Whelton et al[43](#jah31718-bib-0043){ref-type="ref"} found that AE training reduced resting BP to greater levels among Asian (6/7 mm Hg) and Black (11/3 mm Hg) compared to white samples (3/3 mm Hg; *P\<*0.05). In follow‐up analyses (not shown), we observed a similar non‐significant trend where greater SBP reductions occurred among studies that included Hispanic/Latino (≈13/10 mm Hg) and Asian (≈11/10 mm Hg) compared to white samples (≈9/10 mm Hg).

The potential mechanisms underlying the greater BP‐lowering benefits resulting from dynamic RT among non‐white than white samples are beyond the scope of our meta‐analysis, and should be interpreted with some caution because we estimated race/ethnicity based on the study location for ≈86% of included studies. Nonetheless, we examined racial/ethnic differences in baseline study‐level characteristics to determine whether these covariates could provide additional insight to our findings. Despite similar baseline BP (white: 128.0±9.9/76.9±8.9 mm Hg vs non‐white: 125.0±10.6/76.6±8.7 mm Hg; *Ps≥*0.90), we found that body mass index was higher among studies with white than non‐white samples (27.9±0.5 vs 25.6±0.6 kg/m^2^; *P*=0.01), and waist circumference tended to be greater among non‐white than white study samples (100.1±8.2 vs 92.2±9.5 cm; *P=*0.10). However, these study‐level covariates did not emerge as moderators of BP response to dynamic RT, perhaps in part, because they were poorly reporting across interventions (body mass index, k*=*60; waist circumference, k*=*17). Therefore, follow‐up analyses did not provide any additional insight into our findings as to why greater antihypertensive effects were observed among RT studies that included non‐white than white samples.

Limitations, Strengths, and Future Directions {#jah31718-sec-0029}
---------------------------------------------

Our meta‐analysis is not without limitations. The broader selection criteria, which permitted RCTs and non‐RCTs and studies that included samples with and without CVD‐related chronic diseases and health conditions, may limit our ability to directly compare our findings against previous meta‐analyses. On the other hand, subsequent analyses did not reveal that randomization or inclusion of study samples with CVD‐related chronic diseases or health conditions significantly modulated the BP response to dynamic RT. Moreover, our multiple moderator models controlled for potential biases that could have been introduced by including studies presumed to be of "lower quality" (ie, non‐RCTs). We must also acknowledge that estimating race/ethnicity based on the geographical location of the study is a limitation of our meta‐analysis, but more importantly, a limitation of primary‐level studies in this literature.[134](#jah31718-bib-0134){ref-type="ref"}, [135](#jah31718-bib-0135){ref-type="ref"}, [136](#jah31718-bib-0136){ref-type="ref"} We estimated race/ethnicity only when it was *unreported* in the original article; unfortunately, this was the case for the majority of our sample. Nonetheless, we employed the same methodology used by Whelton et al[43](#jah31718-bib-0043){ref-type="ref"} and 2 recent meta‐analyses that examined differences in prevalence of high BP[45](#jah31718-bib-0045){ref-type="ref"} and diabetes mellitus[44](#jah31718-bib-0044){ref-type="ref"} between racial/ethnic minority groups. Finally, our results should be interpreted with some caution because the effect modifiers we observed using study‐level moderators may not be confirmed in future studies using individual participant‐level.[137](#jah31718-bib-0137){ref-type="ref"}, [138](#jah31718-bib-0138){ref-type="ref"}

Our meta‐analysis also has several strengths. In addition to fully satisfying contemporary methodological standards, our meta‐analysis is one of the largest, most comprehensive meta‐analyses conducted on this topic to date. We included 64 controlled studies (71 interventions) that involved 2374 participants, of which 1968 had pre‐ to established hypertension. Second, we expanded upon previous meta‐analyses by applying more sophisticated, contemporary approaches (ie, multiple moderator meta‐regressions[16](#jah31718-bib-0016){ref-type="ref"}, [18](#jah31718-bib-0018){ref-type="ref"}, [19](#jah31718-bib-0019){ref-type="ref"}) and innovative techniques (ie, interactive modeling strategies[51](#jah31718-bib-0051){ref-type="ref"} and the moving constant technique[67](#jah31718-bib-0067){ref-type="ref"}) that enabled us to identify novel study‐level moderators that explained a clinically meaningful proportion of the variance in the BP response to dynamic RT (ie, 50--67%). Third, our meta‐analysis incorporated methodological study quality and other potential biases (ie, BP‐focused outcomes) into our multiple moderator models; therefore, we can be more confident in the robustness of our findings despite the methodological limitations of this literature. Last, our results may also help to optimize future research efforts by documenting where knowledge is the weakest or poorly reported, generating new hypotheses about what dose of dynamic RT elicits optimal antihypertensive benefits for particular patient populations, and highlighting which research areas warrant additional investigation.

Conclusions {#jah31718-sec-0030}
===========

In summary, our meta‐analysis, which adhered to high‐quality, contemporary methodological standards, revealed that dynamic RT can elicit BP reductions that are comparable to, or greater than, those reportedly achieved with AE among samples with hypertension. A novel finding was that dynamic RT conferred the greatest antihypertensive benefit among studies that included non‐white samples with hypertension that were not taking BP‐lowering medication; BP reductions that were double in magnitude to those reported as a result of AE training. Despite our new and exciting findings, this literature has limitations and is of only fair‐to‐moderate quality. Additional RCTs that adequately report the characteristics of their sample, dynamic RT intervention features, and BP assessment methods are needed to confirm our findings. Nonetheless, our results indicate that RT should be further investigated as a viable lifestyle therapeutic option for adult populations with hypertension, and the present exercise recommendations for hypertension should be revisited to include dynamic RT *in addition to* AE as stand‐alone antihypertensive lifestyle therapy.

Sources of Funding {#jah31718-sec-0032}
==================

This research was supported by the Office of the Vice President for Research (Research Excellence Program) and Institute for Collaboration on Health, Intervention, and Policy (InCHIP), both located at the University of Connecticut (Storrs, CT). Dr Paulo V.T. Farinatti was supported by the Brazilian Council for the Scientific and Technological Development (CNPq).

Disclosures {#jah31718-sec-0033}
===========

None.

Supporting information
======================

###### 

**Data S1.** Full search strategy for each of the five electronic databases queried: PubMed, Scopus (including EMBASE), Web of Science, SPORTDiscus, and CINAHL (Cumulative Index to Nursing and Allied Health Literature).

**Data S2.** Augmented version of the Downs and Black Checklist.

**Table S1.** Antihypertensive Effects of Dynamic Resistance Training Compared to Control: A Comparison of Weighted Mean Effect Sizes and Tests for Homogeneity for Systolic and Diastolic Blood Pressure Generated using Stata 13.1 vs the Metafor Package in R (k=71)

**Table S2.** Blood Pressure Response to Dynamic Resistance Training: A Comparison of Multiple Moderator Models Generated Using Stata 13.1 vs the Metafor Package in R

**Table S3.** General Description of Each Included Study and a Detailed Summary of the Baseline Sample Characteristics, Dynamic Resistance Training and Control Interventions, and Blood Pressure Outcomes (k=71)

**Table S4.** Summary of the Overall Methodological Study Quality, Individual Quality Items, and Quality Subscales for the Included Dynamic Resistance Training Interventions (k=71) Gauged Using the Augmented Downs and Black Checklist

**Table S5.** Item‐by‐Item Summary of Methodological Study Quality for the Included Dynamic Resistance Training Intervention (k=71) Gauged Using the Augmented Version of the Downs and Black Checklist

**Table S6.** Resting Blood Pressure Assessment Methods for Preintervention and Postintervention Measurements (k*=*71)

**Table S7.** Antihypertensive Effects of Dynamic Resistance Training vs Control: Weighted Mean Effect Sizes and Test for Homogeneity for Systolic and Diastolic Blood Pressure

**Figure S1.** Tests for publication bias using Begg and Egger methods: systolic blood pressure.

**Figure S2.** Tests for publication bias using Begg and Egger methods: diastolic blood pressure.
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